Literature DB >> 6940181

Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.

I J Fidler, S Sone, W E Fogler, Z L Barnes.   

Abstract

The multiple systemic administration of multilamellar liposomes composed of phosphatidylserine and phosphatidylcholine (molar ratio 3:7) that contained water-soluble muramyl dipeptide (MDP) activated alveolar macrophages to become tumoricidal and eradicated established spontaneous pulmonary and lymph node metastases. Spontaneously metastasizing melanoma cells were injected into the footpads of mice. After 4-5 weeks, the tumors were resected by a midfemoral amputation; 3 days later, twice-weekly injections of liposomes were initiated and continued for 4 weeks. In some experiments the mice were killed 2 weeks after the final treatment. Seventy-four percent of animals injected with liposomes containing MDP were free of visible metastases. In a separate life-span experiment, 60% of mice treated with liposome-encapsulated MDP were tumor-free 120 days after the last liposome treatment or 110 days after all control mice treated with free MDP or control liposome preparations had died of disseminated cancer. These data suggest that the systemic administration of liposomes containing MDP, or similar compounds that produce macrophage activation, may provide an additional useful approach to the therapeutic regimens currently used to eradicate cancer metastases.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6940181      PMCID: PMC319196          DOI: 10.1073/pnas.78.3.1680

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components.

Authors:  F Audibert; L Chédid; P Lefrancier; J Choay
Journal:  Cell Immunol       Date:  1976-02       Impact factor: 4.868

2.  Recognition and destruction of target cells by tumoricidal macrophages.

Authors:  I J Fidler
Journal:  Isr J Med Sci       Date:  1978-01

3.  Metastasis results from preexisting variant cells within a malignant tumor.

Authors:  I J Fidler; M L Kripke
Journal:  Science       Date:  1977-08-26       Impact factor: 47.728

4.  Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives.

Authors:  F Ellouz; A Adam; R Ciorbaru; E Lederer
Journal:  Biochem Biophys Res Commun       Date:  1974-08-19       Impact factor: 3.575

5.  Consideration of the subcutaneously implanted B16 melanoma as a screening model for potential anticancer agents.

Authors:  D P Griswold
Journal:  Cancer Chemother Rep 2       Date:  1972-11

6.  Production of specific macrophage activating factor by lymphocytes from tumor-bearing mice.

Authors:  M L Kripke; M B Budmen; I J Fidler
Journal:  Cell Immunol       Date:  1977-05       Impact factor: 4.868

7.  Activation in vitro of mouse macrophages by syngeneic, allogeneic, or xenogeneic lymphocyte supernatants.

Authors:  I J Fidler
Journal:  J Natl Cancer Inst       Date:  1975-11       Impact factor: 13.506

8.  Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines.

Authors:  S Sone; G Poste; I J Fidler
Journal:  J Immunol       Date:  1980-05       Impact factor: 5.422

9.  Immunoadjuvant activities of synthetic 6-O-acyl-N-acetylmuramyl-L-alanyl-D-isoglutamine with special reference to the effect of its administration with liposomes.

Authors:  S Kotani; F Kinoshita; I Morisaki; T Shimono; T Okunaga; H Takada; M Tsujimoto; Y Watanabe; K Kato; T Shiba; S Kusumoto; S Okada
Journal:  Biken J       Date:  1977-12

10.  Reduction of tumour cell entry into vessels by BCG-activated macrophages.

Authors:  L A Liotta; C Gattozzi; J Kleinerman; G Saidel
Journal:  Br J Cancer       Date:  1977-11       Impact factor: 7.640

View more
  84 in total

1.  Liposomal muramyl dipeptide therapy of experimental M5076 liver metastases in mice.

Authors:  N C Phillips; M S Tsao
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 2.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

3.  Inhibition of murine hepatic tumor growth by liposomes containing a lipophilic muramyl dipeptide.

Authors:  P Brodt; J Blore; N C Phillips; J S Munzer; J D Rioux
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels.

Authors:  T Asano; K Matsushima; E S Kleinerman
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

Review 5.  Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease.

Authors:  R O Brady; G J Murray; N W Barton
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

6.  Antimetastatic effect of endogenous tumor necrosis factor induced by the treatment of recombinant interferon gamma followed by an analogue (GLA-60) to synthetic lipid A subunit.

Authors:  I Saiki; H Maeda; J Murata; N Yamamoto; M Kiso; A Hasegawa; I Azuma
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Interaction of high or low metastatic related tumor lines with normal or lymphokine-activated syngeneic peritoneal macrophages: in vitro analysis of tumor cell binding and cytostasis.

Authors:  V Schirrmacher; B Appelhans
Journal:  Clin Exp Metastasis       Date:  1985 Jan-Mar       Impact factor: 5.150

Review 8.  Immunology of metastasis. Can the immune response cope with disseminated tumor?

Authors:  P Frost; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

9.  Immunotherapy of Lewis lung carcinoma with hydrosoluble peptidoglycan monomer (PGM).

Authors:  G Sava; T Giraldi; J Tomasić; I Hrsak
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

10.  Effect of quinonyl-N-acetyl muramyl dipeptide on immune responses in tumor-bearing mice.

Authors:  I Saiki; Y Tanio; K I Yamamoto; Y Yamamura; I Azuma
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.